A new publication involving bradykinin appeared on November 12, 2026. The paper, titled "Contribution of angiotensin receptor type II to dermal extravasation caused by bradykinin in mice: Implications for sartan-induced angioedema," was published in Biomedicine & Pharmacotherapy (Biomedecine & Pharmacotherapie).
The study is indexed under PubMed ID 43019844. Bradykinin remains classified as an unapproved compound used in research settings only. This publication record states the title and journal of record but does not disclose study results, conclusions, or data within the scope of this brief.
Readers interested in the broader context of bradykinin research can consult the compound overview for additional background.